Clinical Research Directory

Inclusion Criteria: \- Subjects eligible to participate in this study must meet all of the following criteria: 1. Male or female aged 18-75 years; 2. Patients must provide signed informed consent prior to enrollment, demonstrating the ability to understand and willingness to sign the written informed consent form; 3. Pathologically confirmed diagnosis of intrahepatic cholangiocarcinoma; 4. Locally advanced disease, failure to achieve R0 resection, and absence of distant metastasis; 5. At least one measurable lesion; 6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0; 7. Child-Pugh class A liver function; Exclusion Criteria: \- Subjects who meet any of the following exclusion criteria are not permitted to enroll in this study: 1. Pathologically diagnosed hepatocellular carcinoma, combined hepatocellular-cholangiocarcinoma, or other non-cholangiocarcinoma malignant components; 2. Patients with postoperative recurrence, or those who have previously received PD-1/PD-L1 antibodies, CTLA-4 antibodies, lenvatinib, or chemotherapy; 3. History or current diagnosis of other malignancies; 4. Active tuberculosis infection; 5. Active, known, or suspected autoimmune disease; 6. History of interstitial lung disease, or non-infectious pneumonitis requiring steroid treatment; 7. Significant clinically significant bleeding symptoms within 3 months prior to enrollment, or clear bleeding tendency; 8. Suspected allergy to the investigational drug(s).